ATR and neoplasm: Mechanistically, SMARCA4 loss promotes heterochromatin accumulation and elevates replication stress, rendering tumor cells increasingly dependent on ATR signaling and consequently more vulnerable to ATR inhibitors in vitro and in vivo [294,295].